ATE492285T1 - Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis - Google Patents

Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis

Info

Publication number
ATE492285T1
ATE492285T1 AT04714847T AT04714847T ATE492285T1 AT E492285 T1 ATE492285 T1 AT E492285T1 AT 04714847 T AT04714847 T AT 04714847T AT 04714847 T AT04714847 T AT 04714847T AT E492285 T1 ATE492285 T1 AT E492285T1
Authority
AT
Austria
Prior art keywords
psoriasis
producing
treatment
medicinal product
kahalalide
Prior art date
Application number
AT04714847T
Other languages
English (en)
Inventor
Delso Miguel Angel Izquierdo
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Application granted granted Critical
Publication of ATE492285T1 publication Critical patent/ATE492285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04714847T 2003-02-26 2004-02-26 Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis ATE492285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
PCT/GB2004/000757 WO2004075910A1 (en) 2003-02-26 2004-02-26 Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Publications (1)

Publication Number Publication Date
ATE492285T1 true ATE492285T1 (de) 2011-01-15

Family

ID=9953685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04714847T ATE492285T1 (de) 2003-02-26 2004-02-26 Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis

Country Status (17)

Country Link
US (2) US7323444B2 (de)
EP (1) EP1596879B1 (de)
JP (1) JP4800194B2 (de)
AT (1) ATE492285T1 (de)
AU (1) AU2004216443B2 (de)
CA (1) CA2516458C (de)
CY (1) CY1111353T1 (de)
DE (1) DE602004030661D1 (de)
DK (1) DK1596879T3 (de)
ES (1) ES2358018T3 (de)
GB (1) GB0304367D0 (de)
MX (1) MXPA05009029A (de)
NZ (1) NZ541493A (de)
PT (1) PT1596879E (de)
RU (1) RU2356908C2 (de)
SI (1) SI1596879T1 (de)
WO (1) WO2004075910A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
JP2011500723A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
JP2011513370A (ja) * 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
TWI807411B (zh) 2017-04-27 2023-07-01 西班牙商瑪製藥股份有限公司 抗腫瘤化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US4853388A (en) * 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
SK88793A3 (en) * 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5932189A (en) 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
JP4386967B2 (ja) * 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7476198A (en) 1997-05-09 1998-11-27 General Hospital Corporation, The Cell proliferation related genes
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
EP1131304B1 (de) * 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl -akrylamid, ein irreversibler tyrosin-kinasen hemmer
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
AU2002210749B2 (en) 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
AU2002334203C1 (en) 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
MXPA05004133A (es) * 2002-10-18 2005-10-05 Pharma Mar Sau Nuevos compuestos antitumorales.
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
AU2004216443A1 (en) 2004-09-10
US20070032412A1 (en) 2007-02-08
RU2005115102A (ru) 2006-02-27
SI1596879T1 (sl) 2011-07-29
JP2007527851A (ja) 2007-10-04
EP1596879A1 (de) 2005-11-23
EP1596879B1 (de) 2010-12-22
CA2516458A1 (en) 2004-09-10
ES2358018T3 (es) 2011-05-04
WO2004075910A1 (en) 2004-09-10
CY1111353T1 (el) 2015-08-05
CA2516458C (en) 2012-11-27
AU2004216443B2 (en) 2009-03-19
NZ541493A (en) 2008-07-31
US20080090757A1 (en) 2008-04-17
RU2356908C2 (ru) 2009-05-27
US7323444B2 (en) 2008-01-29
GB0304367D0 (en) 2003-04-02
DE602004030661D1 (de) 2011-02-03
JP4800194B2 (ja) 2011-10-26
DK1596879T3 (da) 2011-04-11
PT1596879E (pt) 2011-02-23
MXPA05009029A (es) 2005-11-23

Similar Documents

Publication Publication Date Title
ATE534650T1 (de) Neue cyanothiazolide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MX2010004074A (es) Combinacion 059.
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
EA200901555A1 (ru) Композиция местного применения по уходу за кожей и способ лечения
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
DE10337184A1 (de) Substituierte 3-Pyrrolidin-Indol-Derivate
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE293976T1 (de) Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE69620755D1 (de) Myrteextrakt enthaltendes haarpflegemittel, verfahren zur herstellung und verwendung insbesondere für eine antischuppenbehandlung
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1596879

Country of ref document: EP